Source:http://linkedlifedata.com/resource/pubmed/id/16724093
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
19
|
| pubmed:dateCreated |
2006-9-19
|
| pubmed:abstractText |
HER-2/neu is a candidate for developing breast cancer-targeted immunotherapeutics. Although DNA-based and HER-2/neu transgene-modified dendritic cell (DC)-based vaccines are potent at eliciting HER-2/neu-specific antitumor immunity, there has been no side-by-side study comparing them directly. The present study utilizes an in vivo murine tumor model expressing HER-2/neu antigen to compare the efficacy between adenovirus (AdVneu)-transfected dendritic cells (DC(neu)) and plasmid DNA (pcDNAneu) vaccine. Our data showed that DC(neu) upregulated the expression of immunologically important molecules and inflammatory cytokines and partially converted regulatory T (Tr)-cell suppression through interleukin-6 (IL-6) secretion. Vaccination of DC(neu) induced stronger HER-2/neu-specific humoral and cellular immune responses than DNA vaccination, which downregulated HER-2/neu expression and lysed HER-2/neu-positive tumor cells in vitro, respectively. In two HER-2/neu-expressing tumor models, DC(neu) completely protected mice from tumor cell challenge compared to partial or no protection observed in DNA-immunized mice. In addition, DC(neu) significantly delayed breast cancer development in transgenic mice in comparison to DNA vaccine (P<0.05). Taken together, we have demonstrated that HER-2/neu-gene-modified DC vaccine is more potent than DNA vaccine in both protective and preventive animal tumor models. Therefore, DCs genetically engineered to express tumor antigens such as HER-2/neu represent a new direction in DC vaccine of breast cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0969-7128
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1391-402
|
| pubmed:meshHeading |
pubmed-meshheading:16724093-Adenoviridae,
pubmed-meshheading:16724093-Adoptive Transfer,
pubmed-meshheading:16724093-Animals,
pubmed-meshheading:16724093-Cancer Vaccines,
pubmed-meshheading:16724093-Cytokines,
pubmed-meshheading:16724093-Dendritic Cells,
pubmed-meshheading:16724093-Gene Expression Regulation,
pubmed-meshheading:16724093-Gene Therapy,
pubmed-meshheading:16724093-Genes, erbB-2,
pubmed-meshheading:16724093-Genetic Vectors,
pubmed-meshheading:16724093-Immunotherapy,
pubmed-meshheading:16724093-Mammary Neoplasms, Experimental,
pubmed-meshheading:16724093-Mice,
pubmed-meshheading:16724093-Mice, Inbred Strains,
pubmed-meshheading:16724093-Mice, Transgenic,
pubmed-meshheading:16724093-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:16724093-Transduction, Genetic,
pubmed-meshheading:16724093-Vaccines, DNA
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
|
| pubmed:affiliation |
Cancer Research Unit, Saskatchewan Cancer Agency, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan, Canada S7N 4H4.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|